Emily Lowe

Emily Lowe has a breadth of experience in the biotechnology industry. Emily began their career in 2005 as a Graduate Researcher at Cedars-Sinai Medical Center, where they established the azoxymethane-dextran sodium sulfate (AOM-DSS) mouse model of colitis-associated colorectal (CAC) cancer. Emily conducted successful research on the role of innate immunity in inflammatory diseases, resulting in three peer-reviewed journal publications that were highly cited in the field. In 2010, they began working at UCLA as an Instructor and Postdoctoral Researcher. In their role as Postdoctoral Researcher, they led an NIH U19-funded aim to develop “induction/kill” strategies to eradicate HIV reservoirs in vivo using genetically engineered immunity and the humanized mouse model. Emily was also a Project Leader and Team Member of a California Institute for Regenerative Medicine (CIRM)-funded Disease Team Project. In 2015, Emily joined Kite Pharma as a Director, Associate Director, Senior Scientist, and Scientist. Most recently, in 2021, they began working as Senior Director at Appia Bio.

Emily Lowe completed their Bachelor of Science in Microbiology and Biochemistry from the University of Washington in 2003. Emily then went on to pursue a PhD in Microbiology, Immunology and Molecular Genetics from the University of California, Los Angeles, which they completed in 2009. Prior to this, they attended H.P. Baldwin High School.